Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2014

View Archived Issues

World MS Day: Recent innovations in stem cell therapies, small molecules and biomarkers

Tufts anti-PAR2 pepducin targeted at pulmonary hypertension

AZTherapies initiates trial of combination therapy in Alzheimer's disease

Abzena formed following PolyTherics and Antitope merger

Johnson & Johnson updates on its Medical Devices and Diagnostics business

BioInvent sells back ADC-1013 rights to Alligator Bioscience

Phase IIb study tests non-viral gene transfer for cystic fibrosis

Animal model of hypertriglyceridemia developed in zebrafish

Discovery and characterization of a small-molecule modulator of EBI2

Human iPS-endothelial cells overexpressing IL-8 receptors inhibit vascular injury

Amakem reports novel ROCK inhibitors

Bristol-Myers Squibb patents new HCV inhibitors

Novel PDE10A inhibitors disclosed by Allergan and Diaxonhit

Bionure's BN-201 promotes myelination in cell-culture assay

Cel-Sci expands phase III study of Multikine to new U.S. site

FDA grants orphan drug status to SAR-650984 for cancer

Norwegian investigators disclose new fusion proteins for allergic diseases

Daiichi Sankyo launches Efient in Japan for patients undergoing PCI

LG Life Sciences patents new FFA4 receptor agonists

Wellcome Trust grant supports Calibr's development of immunotherapy for prostate cancer

FDA issues complete response letter for MoxDuo

InterMune resubmits pirfenidone NDA to the FDA

FDA grants orphan drug designation to Advaxis' ADXS-cHER2 for osteosarcoma

Ganymed reports results from phase IIa gastroesophageal cancer trial

Daiichi Sankyo gains rights to lurasidone in four South American countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...